AHA hyperlipidemia and hypercholesterolemia

Approximately 40% of clinically diagnosed patients with heterozygous familial hypercholesterolemia (HeFH) have pathogenic variants of other lipid-related genes in addition to those of conventional FH genes, according to a study....

The normal delay in age of onset of atherosclerotic cardiovascular disease (ASCVD) in women versus men may be shortened in individuals with familial hypercholesterolemia (FH), according to a study. Researchers found that both...

Cardiovascular guidelines advise statin therapy for adults aged 20-75 with low-density lipoprotein cholesterol (LDL-C) of 190 mg/dL or greater with a goal of lowering LDL-C by 50% or more. Furthermore, early-life accumulation of...

Twice-yearly dosing with inclisiran (after the initial and 3-month doses) provided effective and sustained lipid lowering in patients, irrespective of their baseline BMI, and was generally well tolerated, according to a study....

The American Heart Association’s Scientific Sessions 2021 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care...

Scientific Sessions Programming For Presenters and Moderators Specialty Focused Programming Late-Breaking Science Online Program Planner CME/CE Credit Mobile Meeting Guide Live Sessions Session CH.AOS.463 226 – Impact of...

The upcoming presentations of clinical and non-clinical data from its cardiovascular pipeline, including several of its investigational antisense medicines for cardiovascular disease, at the American Heart Association (AHA)...